Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06970847 · ClinicalTrials.gov registry record · Phase 3

64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer

A Phase 3 study of Prostate Cancer and Prostate Cancer Recurrent, sponsored by Clarity Pharmaceuticals.

Recruiting
Registry status
Phase 3
Development phase
220
Enrollment target
20
Study locations

NCT06970847 is a Phase 3 study of Prostate Cancer and Prostate Cancer Recurrent that is actively recruiting participants, run by Clarity Pharmaceuticals. The registered enrollment target is 220 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 17 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06970847, a Phase 3 study of Prostate Cancer and Prostate Cancer Recurrent, is actively recruiting participants, sponsored by Clarity Pharmaceuticals.

RECRUITING
Registry status
Phase 3
Development phase
220 participants
Enrollment target
20
Study locations

Study Summary

The aim for this study is to investigate the ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancer

Conditions Studied

Prostate Cancer Prostate Cancer Recurrent Prostate Cancer Patients Treated by Radiotherapy Prostate Cancer Patients With Detectable PSA Following Prostatectomy Prostate Cancer Patients Who Have Brachytherapy Seed Implant Cryotherapy

Interventions

  • DRUG 64Cu-SAR-bisPSMA

Study Locations (20)

California

  • UC Irvine - Irvine
  • Comprehensive Urology Medical Group - Los Angeles
  • Alarcon Urology Center - Montebello

Florida

  • University of Florida Health- Jacksonville - Jacksonville
  • Biogenix Molecular - Miami

Arizona

  • East Valley Urology Center of Arizona - Mesa

Arkansas

  • Arkansas Urology Research Center - Little Rock

Illinois

  • Endeavor Health - Evanston

Indiana

  • Indiana University Health-IU Simon Cancer Center - Indianapolis

Kansas

  • Wichita Urology Group - Wichita

Louisiana

  • XCancer Research Network / LCMC Health EJGH - Metairie

Trial Details

FieldValue
Enrollment Target 220 participants
Start Date 2025-05-16
Est. Completion 2026-12-31
Phase Phase 3

Sponsor

Clarity Pharmaceuticals

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06970847

The ClinicalTrials.gov registry entry for NCT06970847 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (64% lower). The listed sponsor is Clarity Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which 64Cu-SAR-bisPSMA is the first listed.

NCT06970847 reports 20 study locations spanning 17 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT06970847 about?

NCT06970847 is a clinical study titled "64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer". The aim for this study is to investigate the ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancer

What is the current status of trial NCT06970847?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 220 participants. The study started on 2025-05-16. Estimated completion is 2026-12-31.

What conditions does trial NCT06970847 study?

This clinical trial studies the following conditions: Prostate Cancer, Prostate Cancer Recurrent, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer Patients With Detectable PSA Following Prostatectomy, Prostate Cancer Patients Who Have Brachytherapy Seed Implant.

What interventions are being tested in trial NCT06970847?

The interventions under investigation include: 64Cu-SAR-bisPSMA (DRUG).

Who is sponsoring clinical trial NCT06970847?

This trial is sponsored by Clarity Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06970847 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Prostate Cancer Recurrent

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.